Clene

CLNN

Market cap $57.9M

Overview Fund Activity

5.80 USD

-0.38

6.15%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

5.77

-0.03

0.52%

1 day

-6.15%

5 days

-4.92%

1 month

56.76%

3 months

42.16%

6 months

31.82%

Year to date

7.61%

1 year

-8.52%

5 years

-97.34%

10 years

-96.99%

About: Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.

Employees: 76

Consumer Staples Packaged Foods

0

Funds holding %

of 7,462 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

125% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 4

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

62% more capital invested

Capital invested by funds: $1.4M [Q1] → $2.27M (+$868K) [Q2]

1.19% more ownership

Funds ownership: 5.28% [Q1] → 6.46% (+1.19%) [Q2]

4% less funds holding

Funds holding: 24 [Q1] → 23 (-1) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$23

297% upside

Avg. target

$34

486% upside

High target

$48

728% upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

Benchmark Bruce D. Jackson	$31	Buy Maintained	10 Sep 2025
D. Boral Capital Jason Kolbert	$23	Buy Maintained	21 Aug 2025
Canaccord Genuity Sumant Kulkarni	$48	Buy Maintained	18 Aug 2025

See Analyst Rankings

Financial journalist opinion

Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson's Disease

SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurological diseases, today announced new preclinical data showing that CNM-Au8® improved key measures of cellular health in a novel dopaminergic neuron model of Parkinson's disease (PD). The study results will be presented today at the Michael J. Fox Foundation H2 Therapeutics Stewardship Meeting in New York City by Associate Professor Jerome Mertens, who conducted the study in collaboration with Dr. Fred Gage of the Salk Institute, and Karen S. Ho, Ph.D., Vice President of Translational Medicine of Clene. The work was supported by funding from the Michael J. Fox Foundation (MJFF).

Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson's Disease

Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference

SALT LAKE CITY, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the H.C.

Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Zacks Investment Research

Clene Inc. (CLNN) Reports Q2 Loss, Misses Revenue Estimates

Clene Inc. (CLNN) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to a loss of $1.06 per share a year ago.

Clene Inc. (CLNN) Reports Q2 Loss, Misses Revenue Estimates

Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights

SALT LAKE CITY, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced its second quarter 2025 financial results, provided recent updates on its CNM-Au8 programs and announced sufficient cash runway into the first quarter of 2026.

Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights

Clene to Present at the Emerging Growth Conference

SALT LAKE CITY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference. Virtual Presentation Details Date: August 20, 2025 Time of Presentation: 2:20 p.m.

Clene to Present at the Emerging Growth Conference

Clene to Present at the Canaccord 45th Annual Growth Conference

SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Canaccord 45th Annual Growth Conference and host 1x1 investor meetings. Date: August 12th, 2025 Time of Presentation: 3:30pm ET Location: Boston, MA Format: Presentation 1x1 Meetings: Please contact your Canaccord representative A webcast of the presentation will be available on the “Events” section of the Clene website.

Clene to Present at the Canaccord 45th Annual Growth Conference

Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings

FDA provides supportive feedback on proposed statistical analysis plan for neurofilament biomarker analysis of Clene's NIH-sponsored Expanded Access Program NfL EAP biomarker analyses to be conducted early in the 4 th Quarter of 2025 Clene confirms two additional FDA meetings scheduled for 3 rd Quarter of 2025, to discuss ALS survival data and MS clinical development program Submission of new drug application for ALS under the accelerated approval pathway on track for potential submission in the 4 th Quarter of 2025 SALT LAKE CITY, June 30, 2025 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to advancing therapies for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today provided a regulatory update following a Type C meeting with the U.S. Food and Drug Administration (FDA), and announced two additional meetings scheduled with the FDA in the 3rd quarter of 2025. In the recently concluded Type C meeting, Clene discussed its proposed statistical analysis plan (SAP) for comparing neurofilament light (NfL) biomarker data from its ongoing NIH-sponsored Expanded Access Protocol (EAP), supporting nearly 200 people living with ALS treated with compassionate use of CNM-Au8®, to matched ALS controls.

Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings

Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025

SALT LAKE CITY, UT / ACCESS Newswire / June 9, 2025 / Clene Inc. announced that Rob Etherington, Chief Executive Officer and President, will be presenting at the Investor Summit Virtual taking place on June 10. About Clene Inc. Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis.

Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025

Zacks Investment Research

Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates

Clene Inc. (CLNN) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $1.10. This compares to loss of $1.80 per share a year ago.

Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates

Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights

Clene preparing for upcoming meeting in the second quarter with the U.S. Food and Drug Administration (FDA) to reach agreement on its statistical analysis plan (SAP) regarding analysis of neurofilament light chain (NfL) biomarker data Clene collecting NfL biomarker data from its large National Institute of Health (NIH)-sponsored Expanded Access Protocol (EAP), for evaluation in the third quarter to satisfy the FDA recommendation for additional NfL data Clene reported new data supporting the remyelination and neuronal repair associated with CNM-Au8 ® treatment in a late-breaking science session at the American Academy of Neurology (AAN) 2025 Annual Meeting Clene released new data from a cross-regimen analysis of HEALEY ALS Platform Trial, showing that CNM-Au8 significantly extends survival in patients with ALS Clene planning to submit a New Drug Application (NDA) in the fourth quarter of 2025 for potential Accelerated Approval of CNM-Au8 in ALS Cash and cash equivalents of $9.8 million as of March 31, 2025, providing cash runway into the third quarter of 2025 SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced its first quarter 2025 financial results and provided recent updates on its CNM-Au8 programs. “Prolonging survival for people living with ALS is the critical mission for Clene.

Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights

See News Rankings

Charts implemented using Lightweight Charts™